Review Article
    Pharmacognosy Reviews
    Vol. 7
    Issue 14
    2013
    pp. 117-120
    Open Access

    Thymoquinone in the clinical treatment of cancer: Fact or fiction?

    Majed M. AbuKhader1
    1Department of Pharmacy, Oman Medical College, Muscat, SULTANATE OF OMAN.
    Correspondence:

    *Majed M. AbuKhader

    Department of Pharmacy, Oman Medical College, Muscat, SULTANATE OF OMAN.

    majed.abukhader@omc.edu.om

    Copyright:

    2014 Author(s)

    Check for updates
    Published:24/10/2013
    Received: 13/02/2013

    Abstract

    Thymoquinone (TQ) is the bioactive phytochemical constituent of the seeds oil of Nigella sativa. In vitro and in vivo research has thoroughly investigated the anticancer effects of TQ against several cancer cell lines and animal models. As a result, a considerable amount of information has been generated from research thus providing a better understanding of the anti‑proliferating activity of this compound. Therefore, it is appropriate that TQ should move from testing on the bench to clinical experiments. The purpose of this review is to highlight the potential of TQ as an anticancer agent and the chances of this compound in the clinical treatment of cancer, with special attention on breast cancer treatment.

    Share on Mobile

    Scan to access on mobile

    Keywords

    Breast cancer
    drug delivery
    pharmacokinetics
    thymoquinone
    No content available

    Related Articles